Day: February 14, 2023

Press Release Nokia and Kyndryl expand global network and edge computing allianceThree-year agreement extends plans to co-innovate and accelerate deployment of flexible, reliable, and secure LTE and 5G private wireless connectivity services and Industry 4.0 solutions. Kyndryl elevates its strategic investment in Nokia achieving the highest tier Nokia Digital Automation Cloud (DAC) accreditation status, increasing expert resources and skilled practitioners ready to support customers across the globe. Kyndryl and Nokia will launch a partner innovation lab in Raleigh, North Carolina, to bring advanced wireless connectivity and edge computing, integrated with a multi-factor zero trust model, converging IT and OT for enterprises.14 February 2023 Espoo, Finland and New York, NY – Nokia and Kyndryl, the world’s largest IT infrastructure...

–As part of China’s second booster campaign, Clover’s premium, broadly protective protein-based vaccine is now available in Zhejiang province with additional provinces and municipalities to follow in Q1 2023– SHANGHAI, China, Feb. 14, 2023 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that the launch of its COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in the People’s Republic of China has begun with the first doses delivered and administered in Changxing, Zhejiang as part of China’s national second booster dose (fourth vaccination dose) campaign targeting older adults, immunocompromised individuals and individuals...

Perth, Feb. 14, 2023 (GLOBE NEWSWIRE) — HALF YEAR REPORT INVESTOR WEBINAR / CALL Perth, Western Australia/February 14, 2023/Perseus Mining Limited (ASX/TSX: PRU) is hosting an investor webinar and conference call to discuss its   December 2022 Half Year Results, which are anticipated for release around 8:30am AEDT on Thursday February 23, 2023. CALL DETAILSAustralia: Thursday February 23, 2023 Perth – 6:00am Sydney/Melbourne – 9:00am Canada: Wednesday February 22, 2023 Vancouver – 2:00pm Toronto – 5:00pm UK: Wednesday February 22, 2023 London – 10:00pmRegister for the webinar at the link below: https://us02web.zoom.us/webinar/register/WN_-okmphLRTeedze4IV3chDw After registering, you will receive a confirmation email containing information about joining the webinar. To join the webinar via telephone, please use one of the...

BRISBANE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) — Allkem Limited (ASX|TSX: AKE) (“Allkem” or “the Company”) will release its FY23 Half Year Financial Results on Friday, 24 February 2023. Managing Director and CEO, Mr. Martín Pérez de Solay and Acting CFO, Christian Cortes will conduct a live webcast briefing at 11:00 am AEDT (Sydney, Melbourne) on the same day. To pre-register your details and join the webcast briefing, please follow the link on the homepage of Allkem’s website, www.allkem.co. Written questions may be submitted via the webcast and playback of the briefing and Q&A session will also be available on the company’s website. This release was authorised by Mr Martin Perez de Solay, CEO and Managing Director of Allkem Limited.Allkem Limited ABN 31 112 589 910 Level 35, 71 Eagle StBrisbane, QLD 4000 Investor...

Figure 1 Map of the 2022 drilling programFigure 2 Map of new claims for LiMONTRÉAL, Feb. 13, 2023 (GLOBE NEWSWIRE) — NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) would like to provide an update on the delay in the delivery of assay results following the drilling program on the “extension” of the Crevier project (the “Crevier Extension”), in addition to increase in the Company’s land position in Quebec. Delay in receiving analyses on the Crevier ExtensionThe Company wishes to inform that it is currently facing delays in the delivery of assay results from the 2022 drilling campaign. (PR December 2022). The Company will issue a press release when it has validated the results obtained, respecting the established standards. Figure 1: Map of the 2022 drilling programhttps://www.globenewswire.com/NewsRoom/AttachmentNg/56dca8e0-537d-468a-b123-3aa48b94f93d Staking...

Glass Lewis Recognizes that Change Led by Amarin’s New Board is Already Underway, and Sarissa Representation is Not Warranted Report Notes that Sarissa’s Underqualified Slate of Nominees Include “Redundant” Skillsets Amarin Board Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that leading independent proxy advisory firm, Glass Lewis & Co (Glass Lewis) has recommended that shareholders vote “AGAINST” all of Sarissa’s proposals at the Company’s General Meeting to be held on February 28, 2023. In its February 13, 2023, report, Glass Lewis recognized that significant changes have already been made at Amarin over the last 18 months and noted Sarissa...

CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan Oncology has entered into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 (CLN-418) in the U.S. CLN-418/HBM7008 is a B7H4 x 4-1BB bispecific immune activator developed from next-gen heavy chain only antibody (HCAb)-based multi-specific antibody discovery platform HBICE®, currently in a Phase 1 clinical study being conducted at U.S. and Australian sites in patients with advanced solid tumors. “We are pleased to bring CLN-418, a potential first-in-class, clinical-stage bispecific immune activator, into our diversified portfolio. We believe the best approach to conditional activation of 4-1BB is by targeting B7H4, a tumor associated antigen...